Legend Capital, a venture capital firm headquartered in Beijing, China, focuses on early-stage and growth-stage investments in innovative and high-growth enterprises primarily within China or related to China. Their strategy involves investing across sectors such as technology, healthcare, consumer, enterprise services, and intelligent manufacturing, while providing strategic guidance and operational support to their portfolio companies.
31% of their portfolio is in Biotech & Life Sciences. Deal activity increased 50% year-over-year (3 deals in the last 12 months). Average disclosed round size is $102.0M (across 10 rounds with reported amounts).
Portfolio
13
Fund Size
$10B
Top Stage
Series B
Last 12 Mo
3
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
13 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Viture | Series D | $100M | Feb 2026 |
 Obita | Seed | — | Jan 2026 |
| Obita | Seed | — | Dec 2025 |
 Angitia Biopharmaceuticals | Series C | $120M | Dec 2024 |
| AAllink Biotherapeutics | Series A | $42M | Nov 2024 |
 Zhipu AI | Series B | — | Sep 2022 |
| CClinChoice | Series E | $150M | Jul 2022 |
| MMediLink Therapeutics | Series B | $70M | Mar 2022 |
 Lynk Pharmaceuticals | Series B | $50M | Aug 2021 |
 Innovent Biologics, Inc. | Series E | $150M | Apr 2018 |
 Wish | Series C | $50M | Jun 2014 |
| Viture | Growth | $100M | — |
| IInceptio Technology | Series D | $188M | — |
Top Co-Investors
Lilly Asia Ventures3 shared
Vision Plus Capital2 shared
Meituan2 shared
Mirana Ventures1 shared
OrbiMed1 shared
Gaorong Capital1 shared
Cormorant Asset Management1 shared
Rock Springs Capital1 shared
Ally Bridge Group1 shared
Temasek Holdings1 shared
Hillhouse Capital1 shared
LYFE Capital1 shared
Loyal Valley Capital1 shared
HighLight Capital1 shared
Alliance Ventures1 shared
Med-Fine Capital1 shared
Sequoia China1 shared
Eight Roads Ventures1 shared
Founders Fund1 shared
Yahoo1 shared
Last updated: 5 March 2026